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New strategies for immune modulation have shown real promise in regenerative medicine as well as the fight
against autoimmune diseases, allergies, and cancer. Dendritic cells (DCs) are gatekeepers of the immune system
and their ability in shaping the adaptive immune responses makes DCs ideal targets for immune modulation.
Carbohydrates are abundant in different biological systems and are known to modulate DC phenotype and
function. However, how simple monosaccharides instruct DC function is less well understood. In this study, we
used a combinatorial array of immobilized monosaccharides to investigate how they modulate DC phenotype and
function and crucially the impact of such changes on downstream adaptive immune responses. Our data show that
a selection of monosaccharides significantly suppress lipopolysaccharide-induced DC activation as evidenced by a
reduction in CD40 expression, IL-12 production, and indoleamine 2,3-dioxygenase activity, while inducing a
significant increase in IL-10 production. These changes are indicative of the induction of an anti-inflammatory or
regulatory phenotype in DCs, which was further confirmed in DC–T cell co-cultures where DCs cultured on the
‘regulatory’ monosaccharide-coated surfaces were shown to induce naïve T cell polarization toward regulatory
phenotype. Our data also highlighted a selection of monosaccharides that are able to promote mixed Treg and
Th17 cell differentiation, a T cell phenotype expected to be highly immune suppressive. These data show the
potential immunomodulatory effects of immobilized monosaccharides in priming DCs and skewing T cell dif-
ferentiation toward an immune-regulatory phenotype. The ability to fine-tune immune responses using these
simple carbohydrate combinations (e.g. as coatings for existing materials) can be utilized as novel tools for im-
mune modulation with potential applications in regenerative medicine, implantable medical devices, and wound
healing where reduction of inflammatory responses and maintaining immune homeostasis are desirable.1. Introduction
The immune system plays a central role in response to foreign ma-
terials we are exposed to, from pathogens to biomaterials used for ther-
apeutic purposes [1]. The ability to suppress adverse immune responses
and promote beneficiary regulatory and pro-healing immune responses, Dendritic cells; DC-SIGN, Dend
tor; MFI, Median fluorescence in
100% 1-amino-1-deoxy-β-D-galac
annose; (Gal2–Man2), 2-amino-2
oxy-β-D-mannose; (Gal1–Gal2), 5
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vier Ltd. This is an open access awill improve the clinical outcome for implanted materials whether used
as scaffolds for regenerative medicine applications or in medical devices
[2]. Dendritic cells (DCs) are the immune system's sentinels that sense
their surrounding environment using a host of different pattern recog-
nition receptors (PRRs) [3]. Upon activation, DCs migrate to draining
lymph nodes where they prime naïve T cells and instruct theirritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin; IDO,
tensity; PRR, Pattern recognition receptor; LPS, Lipopolysaccharide; FBS, Fetal
tose; (Gal2), 100% 2-amino-2-deoxy-β-D-galactose; (Gal2–Man1), 90% 2-amino-
-deoxy-β-D-galactose þ 10% 2-amino-2-deoxy-β-D-mannose; (Man1–Man2), 40%
0% 1-amino-1-deoxy-β-D-galactose þ 50% 2-amino-2-deoxy-β-D-galactose.
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Treg, or Th17), a process that is heavily influenced by DCs' surface
phenotype, cytokine profile, and expression of other immune-regulatory
molecules [4–6]. DCs constantly sample their environment using PRRs,
which enable them to transfer information about the nature of antigens
and foreign materials they have encountered in peripheral tissues to T
cells in lymph nodes [7]. Carbohydrates are an integral part of almost all
proteins and play key roles in biological processes including self and
non-self recognition pathways and their associated signaling pathways.
The wide range of functions carried out by carbohydrates is reflected in
their structural diversity [8,9]. The C-type lectin receptors (CLRs) are
amongst many PRRs expressed by DCs and belong to a family of
carbohydrate-binding proteins that recognize a broad repertoire of self
and non-self ligands, with diverse functions in innate and adaptive im-
munity and maintaining homeostasis [10]. Different CLRs recognize
different carbohydrate moieties, and interaction between a given CLR
and its ligand could influence DC phenotype and cytokine profile as well
as downstream events leading to T cell polarization [11,12]. Prime ex-
amples of these are the carbohydrate moieties decorating allergens and
pathogen glycoproteins, which modulate the immune response depend-
ing on their CLR counterparts [12–15] leading to inflammatory responses
or immune evasion [16–18]. In parallel to their role in initiating immune
responses, DCs also play a key role in maintaining tissue homeostasis and
immune regulation. Immune regulatory enzymes, such as indoleamine 2,
3-dioxygenase (IDO), have been implicated in these processes [19,20].
IDO is a rate-limiting enzyme that converts L-tryptophan into kynurenine,
a metabolite with well-established immune-modulatory properties [13,
21,22]. This is exemplified in tumors with high IDO activity leading to
depletion of tryptophan and an increase in kynurenine levels that sup-
presses the immune activity that contributes to the survival of the tumor
[23].
Different surface-modification strategies have been used to develop
materials with higher immune compatibility or the ability to modulate
immune responses [24]; however, despite their strong immune-modu-
latory properties, carbohydrates have not been extensively considered in
this context. While extensive literature on the immune-modulatory
properties of polysaccharides exist, the immune-modulatory potential of
monosaccharides is not well studied. This is despite many advantages in
using monosaccharides in immune modulation including the ability to
synthesize, modify, and characterize highly pure preparations. In this
study, we use a combinatorial library of polymer-tethered surfa-
ce-immobilized monosaccharides (manno-, galacto-, and fuco-) and
investigate their impact on DC phenotype, cytokine profile, and IDO
activity, as well as the ability of carbohydrate primed DCs to instruct T
cell differentiation toward distinct functional phenotypes.
2. Materials and methods
2.1. Generation of human DCs from peripheral blood monocytes
This was done as we have previously described [25]. Briefly, buffy
coats were obtained from healthy donors following ethics committee
approval and informed written consent (National Blood Service, UK).
Separation of peripheral blood monocytes (PBMCs) was done by means
of density gradient centrifugation using Histopaque (Sigma-Aldrich, UK).
CD14þ monocytes were isolated using magnetic-assisted cell sorting
(Miltenyi Biotec, UK). The purity of isolatedmonocytes was confirmed by
flow cytometry and it was consistently >95% (Supplementary Fig. 1).
Purified CD14 monocytes were supplemented with RPMI media con-
taining 10% heat-inactivated fetal bovine serum (FBS), 100 mg/mL
streptomycin, 100 U/mL penicillin, and 2 mM L-glutamine (all from
Sigma-Aldrich). To generate immature DCs, monocytes were then seeded
(1 106 cells per well) in a 24-well tissue culture plate with the presence
of 50 ng/mL GM-CSF and 250 U/mL IL-4 (both fromMiltenyi Biotec) and
incubated at 37 C in a 5% CO2-humidified incubator for 6 days for
differentiation, where fresh media was added on day 3. Immature DC2
phenotype and maturation were confirmed through flow cytometry
(Supplementary Fig. 2).
2.2. Polymerization of N-hydroxyethyl acrylamide
N-Hydroxyethyl acrylamide (1 g, 8.69 mmol), pentafluorophenyl 2-
(dodecylthiocarbonothioylthio)-2-methyl propionic acid (PFP-DMP)
(0.1844 g, 0.35 mmol), and 4,40-azobis (4-cyanovaleric acid) (ACVA)
(0.0195 g, 0.069 mmol) were dissolved in 50:50 toluene:methanol
(4 mL). Mesitylene (150 μL) was added as an internal reference. An
aliquot was taken for NMR analysis in CDCl3. The solution was degassed
under N2 for 30 min. The reaction was stirred at 70 C for 90 min. An
aliquot was taken for NMR analysis in MeOD to determine conversion.
The reaction was rapidly cooled in liquid nitrogen and precipitated into
diethyl ether. The polymer was reprecipitated into diethyl ether from
methanol twice to yield a yellow polymer product that was dried under
vacuum (97% conversion by NMR, Mn (theoretical) ¼ 3,400 g/mol, Mn
(SEC) ¼ 4,100 g/mol, Mw/Mn (SEC) ¼ 1.14).
2.3. Synthesis of 1-amino-1-deoxy-mannose, -galactose, and -fucose
Galactose, mannose, and fucose (1 g) were stirred in 10 mL aqueous
saturated ammonium carbonate for 2–5 days, ensuring the solution
remained saturated. Reaction completion was determined by mass
spectrometry. After completion of the reaction, the solution was freeze-
dried. Excess ammonium carbonate was removed by addition of warm
methanol. After complete evolution of CO2, the methanol was removed in
vacuo. ESI-MS: 1-amino-1-deoxy-mannose (C6H13NO5) M ¼ 179.17 ex-
pected, [2M  H]- observed 359.1 (C12H25N2O10), 1-amino-1-deoxy-
galactose (C6H13NO5) M ¼ 179.17 expected, [2M  H]- observed
359.1 (C12H25N2O10), and 1-amino-1-deoxy-fucose (C6H13NO4)
M ¼ 163.17 expected, [M  H]- observed 162.1.
2.4. End-group modification of PFP-poly(N-hydroxyethyl acrylamide)
(PFP-pHEA) using amino monosaccharides
In a typical reaction, PFP-pHEA (100 mg, 0.029 mmol) and 2-amino-
2-deoxy-galactose (26 mg, 5 eq.) were dissolved in 2 mL DMFwith a drop
of TEA. The reaction was stirred at room temperature for 16 h. The
polymer was precipitated into diethyl ether from methanol three times.
The polymer was dialyzed against water using 1K MWCO tubing to
remove excess unreacted amino-sugar and freeze-dried to result in. IR
indicated the loss of C–O stretch corresponding to the PFP ester and 19F
NMR confirmed the loss of the PFP group. This was carried out with 1-
amino-1-deoxy-β-D-galactose (Gal1), 2-amino-2-deoxy-β-D-galactose
(Gal2), 1-amino-1-deoxy-β-D-mannose (Man1), 2-amino-2-deoxy-β-D-
mannose (Man2), 1-amino-1-deoxy-β-D-fucose, as well as ethanolamine
as a non-monosaccharide terminated control [26,27]. The isomer1 or
isomer2 designation is based on whether the carbohydrate is
amino-functionalized at C1 or C2 of glycan ring and attached to the
N-hydroxyethyl acrylamide polymer by an amide bond (Fig. 1).
2.5. Functionalization of 96-well polystyrene plates with monosaccharide-
functionalized polymers and fabrication of combinatorial monosaccharide
libraries
To make combinatorial libraries of different monosaccharides, a
‘grafting to’ approach was used as we have previously described [28–32]
with minor adjustments. The method involves synthesizing a polymer to
enable anchoring the monosaccharides of interest to the
epoxide-functionalized polystyrene plate. Briefly, the polymer is engi-
neered to have a carbohydrate capture terminus and an immobilization
terminus. N-Hydroxyethyl acrylamide was polymerized to a degree of
polymerization of 20 using reversible addition–fragmentation chain
transfer (RAFT) polymerization mediated by a PFP α-terminated RAFT
agent (Fig. 1A). Monosaccharides (mannose, galactose, and fucose) were
Fig. 1. Synthetic route to carbohydrate-
coated plates. (A) Polymerization of N-
hydroxyethyl acrylamide via RAFT polymer-
ization to a degree of 20 and subsequent
carbohydrate functionalization of pHEA. (B)
Immobilization of carbohydrate-terminated
polymers onto epoxy-coated 96-well plates
[33]. (C) Monosaccharides used in the study
from left to right, 1-amino-1-deoxy galac-
tose, 2-amino-2-deoxy galactose, 1-amino-1--
deoxy mannose, 2-amino-2-deoxy mannose,
and 1-amino-1-deoxy fucose.
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simple substitution of the terminal PFP unit. The
monosaccharide-functionalized polymers were then immobilized onto
3D-epoxy 96-well polystyrene plates using the ω-terminal thiol from the
RAFT agent (Fig. 1B) via a simple incubation and washing steps. To
achieve this, a 0.1 mg/mL solution of monosaccharide-functionalized
pHEA was made up in milliQ water. Solutions of polymers were made
up and 100 μL of each of these solutions was applied to a branched and
spaced (50 nm thickness) epoxy-functionalized flat-bottom 96-well
polystyrene plate and allowed to react for 30 min at room temperature.
Each solution was made in triplicate. After 30 min of incubation, the
solution was removed, and the well was washed with water three times to
remove any unreacted polymer. Various combinations of mono-
saccharides were prepared, ranging from 100% of one monosaccharide
(mannose, galactose, or fucose) to 100% of another (mannose, galactose,
or fucose), in steps of 10% to make a total of 11 different wells in trip-
licate for each library (Supplementary Table 1). This post-polymerization
route ensures that all the polymers have the same initial chain length
distribution and therefore reduced the variability between the libraries
produced but allows for versatile end-group functionalization to make
simple libraries with differing carbohydrate densities.
2.6. Cell culture and screening of DC response
Each of the monosaccharide-functionalized wells was sterilized with
70% ethanol and excess ethanol was washed with sterile PBS. Immature
DCs were incubated in each well for 24 h where each well was seeded
with 1  105 DCs. Some wells were stimulated with LPS from E. coli
(10 ng/mL). Control conditions included well with OH-terminated pHEA
(i.e. no carbohydrate coating), LPS only stimulation, and unstimulated
DCs.
2.7. Quantification of indoleamine 2,3-dioxygenase activity
After stimulation, IDO activity was measured by quantification of the3
levels of kynurenine in the culture supernatant using a colorimetric assay
as we have previously described [25,34,35]. The absorbance was deter-
mined using a Promega GlowMax Explorer plate reader on a wavelength
of 490 nm. The results are plotted against L-kynurenine standards with
concentrations ranging from 0 to 200 mM.
2.8. Flow cytometry
Cells were harvested from the 96-well plates to FACS tubes and
washed with PBA (PBS with 0.5% bovine serum albumin and 0.1% so-
dium azide) as described previously [13]. DCs were then incubated with
labeled antibodies CD274 (APC clone REA1197), CD40 PE (clone HB14),
and CD86 FITC (clone FM95) and isotype-matched mouse antibody
controls (all from Miltenyi Biotec) for 20 min in the dark at 4 C. Cells
were then washed in PBA twice and fixed with 4% paraformaldehyde
until analysis. All samples were analyzed using an FC500 flow cytometer
(Beckman Coulter) and data analysis was carried out using Weasel
software.
2.9. Cytokine quantification
Cell-free culture supernatants were collected and stored at 80 C
before analysis. The levels of cytokines IL-10, IL-12p70, IL-17, IL-4, and
IFNγ were measured by sandwich ELISA using the Duo Set ELISA kit
(R&D Systems, UK) according to manufacturer's instructions.
2.10. Dendritic cells–T cells co-cultures
Autologous co-cultures were carried out with monosaccharides-
primed DC as previously described [25,35]. Briefly, T cells were iso-
lated from PBMCs using a pan T cell isolation kit followed by depletion of
CD45ROþ memory T cells using CD45RO immunomagnetic beads (both
from Miltenyi Biotec). Naïve (CD45RO) T cells were co-cultured with
DCs at a 1:10 DC to T cell ratio in RPMI1640 supplemented with 5%
human AB serum 100 mg/mL streptomycin, 100 U/mL penicillin, and
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plemented with IL-2 (2 ng/mL). After six days of co-culture, cells were
stimulated with anti-CD3 and anti-CD28 overnight followed by quanti-
fying T cells cytokine profile.
2.11. RNA isolation and RT-qPCR
mRNA extraction and isolation were carried out using the RNeasy kit
(QIAGEN) and cDNA synthesis was carried out using a qPCR synthesis kit
(PCR Biosystems) according to the manufacturer's instructions. Real-time
PCR was carried out using SYBR Green qPCR Master Mix (PCRBIOSYS-
TEMS) and the qPCR cycler Stratagene MxPro 3005P qPCR System
(Stratagene, La Jolla, CA). Primers used were GAPDH (forward) 50-
GAGTCAACGGATTTGGTCGT-30, GAPDH (reverse) 50-GACAAGCT
TCCCGTTCTCAG-30; FOXP3 (forward) 50- GTGGCCCGGATGTGAGAAG-
30, FOXP3 (reverse) 50- GGAGCCCTTGTCGGATGATG-30; RORγt (for-
ward) 50- CCTGGGCTCCTCGCCTGACC-30, RORγt (reverse) 50-
TCTCTCTGCCCTCAGCCTTGCC -30. The heat cycle was initiated at 95C
for 2 min, followed by 40 cycles of 95C for 5 s, then 65C for 25 s and
followed by 95C for 1 min, 55C 30 sec and 95C 30 s. Sample values are
relative to LPS only and are normalized to the housekeeping gene
GAPDH. All samples are run in triplicates.
2.12. Statistical analysis
Statistical significance of the data was obtained using GraphPad
Prism 7 (GraphPad Software, San Diego, CA). Therefore, paired t-tests or
ordinary one-way ANOVA was used when comparing between two
groups. Statistically significant p values were considered to be equal to or
lower than 0.05.
3. Results
3.1. Screening a combinatorial library of immobilized mannose, galactose,
and fucose for their ability to modulate DC phenotype
To investigate the effect of surface-immobilized monosaccharides on
DC phenotype and IDO activity, immature and LPS-stimulated DCs wereFig. 2. Flow cytometry data are shown as a heat map summarizing the expression pr
on immobilized monosaccharide libraries in the presence of a TLR4 ligand (LPS). U
expressed as a percentage of expression levels in mature (LPS-stimulated) DCs. A re
reduction in fucose-contained libraries compared to LPS alone. CD86 expression was h
these did not reach statistical significance. CD274 (PD-L1) expression showed a signifi
three independent donors where *p<0.05, **p<0.01, ***p<0.001, and ****p<0.000
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cultured on the monosaccharide-immobilized polystyrene plates con-
taining different ratios of amino-fucose, amino-mannose, and amino-
galactose (where the number after each glycan indicates the ring-
position of the amine, Fig. 1) for 24 h followed by flow cytometric
analysis of their surface phenotype and quantifying kynurenine in the
supernatant as a surrogate for IDO activity. For analyzing DC phenotype,
we chose a selection of surface receptors linked to immune stimulation
(CD40 and CD86) or inhibition (CD274 or programmed death ligand 1
(PDL-1)). Unsurprisingly, none of the monosaccharide combinations
seemed to influence the immature DC phenotype (Supplementary Fig. 3)
since monosaccharides are abundant in the human body contributing to
cell membrane physiology and metabolism; hence, without accompa-
nying a potent stimulus (e.g. a danger signal), the immune cells would
not react to them [36]. However, flow cytometry data (Fig. 2 and Sup-
plementary Figs. 4–7) showed that 35 immobilized monosaccharides
were able to significantly downregulate CD40 expression in
LPS-stimulated DCs. Interestingly, all fucose-containing carbohydrates
induced significant suppression of CD40 expression. This was in contrast
to all Gal1 with Man1 or Man 2 combinations (except 60% Man2 40%
Gal1 and 100% Gal1), which did not induce any significant changes in
CD40 expression. As indicated previously, the isomer1 or isomer2
designation is based on whether the carbohydrate is functionalized at C1
or C2 of the N-hydroxyethyl acrylamide polymer respectively, which
seems to have an impact on how they interact with DCs. Furthermore, we
observed an increase in CD274 (PD-L1) expression in LPS-stimulated DCs
treated with all combinations of Gal2 with Man1 or Man2 indicating a
shift toward regulatory/inhibitory DCs. CD86 expression was higher in a
number of conditions (particularly combinations of Gal1 and Gal2);
however, these did not reach statistical significance (Fig. 2 and Supple-
mentary Figs. 4–6). Nevertheless, at this stage of screening, all mono-
saccharides, regardless of their impact on DCs’ surface phenotype, were
taken forward for additional experimentation.3.2. The effect of immobilized monosaccharides on DC IDO activity
Next, to understand the impact of monosaccharides on DC
immunogenicity, we investigated IDO activity in LPS-stimulated DCs
cultured on a selection of monosaccharides predicted to have pro- orofile of three surface markers (CD86, CD40, and CD274) on DCs after incubation
nstimulated (immature) DCs were used as a negative control. All changes are
duction in CD40 expression was observed in most conditions with the highest
igher in a number of conditions (particularly mixers of Gal1 and Gal2); however,
cant increase in Man1 and Gal2 combinations. Data are shown as mean  SD of
1.
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Data from these experiments show significant reductions in the IDO
activity, particularly in combinations mainly constituted of both iso-
forms of the carbohydrate where the carbohydrate is functionalized at
C1 or C2 of the N-hydroxyethyl acrylamide polymer for isomer1 or
isomer2 respectively (Fig. 3). These findings corroborate observed
changes in DCs phenotype (e.g. suppression of CD40 expression) and
suggest that DCs primed on a number of immobilized mono-
saccharides acquire distinct pro- or anti-inflammatory phenotypes
[37,38]. Interestingly, similar mixtures of monosaccharides in soluble
form did not induce any significant changes in IDO activity (Supple-
mentary Fig. 8).3.3. Immobilized Gal1, Man1–Man2, Man1–Gal2, and Man2–Gal2
significantly increase the production of IL-10 and suppress IL-12 production
while Gal1–Gal2 suppresses both cytokines in TLR4-stimulated DCs
To better understand the effect of different monosaccharides shown
to modulate DC phenotype and IDO activity on DC function, we also
investigated their impact on DC cytokine profile focusing on IL-12 and IL-
10 as prototypic pro- and anti-inflammatory cytokines respectively. DCs
stimulated with LPS and cultured on 100% galactose1 (Gal1), 40%
mannose1 þ 60% mannose2 (Man1–Man2), 10% mannose1 þ 90%
galactose2 (Man1–Gal2), and 10% mannose2 þ 90% galactose2
(Man2–Gal2)-coated wells showed a significant increase in IL-10 while
suppressing IL-12 production compared to LPS only (Fig. 4 and Supple-
mentary Fig. 9). These findings are in line with the observed changes in
the DC phenotype showing suppression in CD40 expression in response
to the same monosaccharide combinations. An intriguing finding was
identifying sugar combinations (e.g. 50% Gal1þ 50% Gal2 (Gal1–Gal2))Fig. 3. Data obtained from indoleamine 2,3-dioxygenase activity in dendritic cells t
(LPS). Reduction in indoleamine 2,3-dioxygenase activity is prominent in monosacc
while others have a reduction in indoleamine 2,3-dioxygenase activity but not as sign
shown as mean  SD of three independent donors where *p<0.05, **p<0.01, ***p<
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that were able to lower DC IDO activity as well as suppressing both IL-10
and IL-12 levels. These carbohydrate combinations are expected to
significantly suppress DC immunogenicity.3.4. Suppressing IDO activity using a competitive inhibitor leads to a
similar cytokine profile to monosaccharide-primed DCs
To investigate whether the observed changes in DCs cytokine profile
could be due to changes in IDO activity, we treated LPS-stimulated DCs
with 1-methyl-DL-tryptophan (MT), a competitive inhibitor of IDO, fol-
lowed by quantifying IL-12 and IL-10 production [22]. The data show that
MT suppressed IDO activity in DCs in a dose-dependent manner (Fig. 5A).
The level of reduction in IDO activity in the chosen MT concentration
range was comparable with the levels observed in DCs primed with Gal1,
Man1–Man2, Man1–Gal2, Man2–Gal2, and Gal1–Gal2. Furthermore, the
MT-treated DCs showed a reduction in IL-12 production, similar to their
monosaccharide-treated counterparts. These data suggest a correlation
between changes in IDO activity and IL-12 production.
Interestingly, in the case of IL-10 in lower concentrations of MT,
where IDO activity is only reduced by around 50%, there is an increase in
IL-10 production, albeit not statistically significant, which is only sup-
pressed with increasing concentrations of MT and marked reduction in
IDO activity to around 10% of LPS only condition. This is consistent with
data from monosaccharide-treated DCs showing that while a 50%
reduction in IDO activity correlates with a significant suppression of IL-
12 production, IL-10 production is increased. Collectively, these data
suggest that DC pro- or anti-inflammatory phenotypes correlate with the
level of IDO activity where a change in IDO is directly proportional to IL-
12 production, whereas IL-10 levels seem to show a biphasic correlation
to IDO activity (Fig. 5B and C).reated with the immobilized monosaccharides in the presence of a TLR4 ligand
haride combinations consisting of the two isomers of the same monosaccharide
ificant as the latter compared to dendritic cells treated with LPS alone. Data are
0.001, and ****p<0.0001.
Fig. 4. Cytokine profile of dendritic cells treated with immobilized monosaccharides in the presence of a TLR4 ligand (LPS). Gal1, Man1–Man2, Man1–Gal2, and
Man2–Gal2 combinations induce a significant increase in IL-10 production and suppression in IL-12 while Gal1–Gal2 suppresses both cytokines in response to LPS
stimulation compared to LPS alone. Data are presented as the percent change compared to levels of cytokines produced in response to LPS stimulation for each donor.
Data are shown as mean  SD of 3 independent donors where *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.
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toward IL-10 and IL-17 producing cells respectively
Gal1, Man1–Man2, Man1–Gal2, Man2–Gal2, and Gal1–Gal2 modu-
lated DC surface stimulatory ligands, cytokine production, and IDO6
activity in LPS-stimulated DCs suggesting a regulatory phenotype. These
conditions were selected for investigating downstream effects on T cell
differentiation in DC–T cell co-culture studies. Co-cultures were carried
out using autologous naïve T cells and DCs, where DCs were primed with
the selected immobilized carbohydrates in the presence of LPS for 24 hFig. 5. DCs were treated with LPS and
varying concentrations of 1-methyl-DL-tryp-
tophan (a competitive indoleamine 2,3-diox-
ygenase inhibitor) to assess the correlation of
IDO activity to IL-10 and IL-12 production.
A) MT suppresses IDO activity in a dose-
dependent manner. B) IL-12 production
shows a proportional relationship with IDO
activity. C) IL-10 production shows a peak in
lower concentrations of the inhibitor
(0.004 mM and 0.01 mM) where IDO is at
50% reduction, while after almost complete
inhibition of IDO activity (at 0.4 mM), there
is still IL-10, but not IL-12 production. Data
presented as mean  SD of 3 independent
donors where *p<0.05, **p<0.01,
***p<0.001, and ****p<0.0001.
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icant increase in IL-10 production by naïve T cells in Gal1, Gal1–Gal2,
and Man2–Gal2 conditions (Fig. 6). An interesting finding was that T
cells co-cultured with Gal1 and Gal1–Gal2 treated DCs showed a signif-
icant increase in IL-17 production compared to LPS alone, whereas a
decrease in IL-17 can be noted in Man1–Gal2. These data also show a
significant decrease in IL-4 production by T cells co-cultured with
Gal1–Gal2 and Man2–Gal2 treated DCs while IFN-γ levels remain un-
changed compared to LPS alone for all conditions.
From these data, we hypothesized that naïve T cells co-cultured
with Gal1 and Gal1–Gal2 treated DCs have acquired mixed anti-
inflammatory and pro-inflammatory phenotypes similar to what hasFig. 6. Co-cultures of T cells with monosaccharide-primed DCs were set up to invest
profile. IL-10, IFNγ, IL-4, and IL-17 were selected as prototypic Treg, Th1, Th2, and
reaching statistical significance in Gal1, Gal1–Gal2, and Man2–Gal2. Interestingly, t
increase observed in Gal1 and Gal1–Gal2. A significant decrease in IL-17 can be note
into Th1. Data are shown as mean  SD of 4 independent donors where *p<0.05,
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been recently described in the context of some inflammatory condi-
tions and cancers [39]. To further confirm the phenotype of these
cells, we investigated the expression of FOXp3 and RORγt, major Treg,
and Th17 transcription factors respectively, using real-time polymer-
ase chain reaction (RT-PCR). We were able to confirm the expression
of both FOXp3 and RORγt, indicating the generation of cells with a
mixed Treg/Th17 phenotype on immobilized Gal1 and Gal1–Gal2
(Fig. 7). Interestingly, Man1–Gal2 showed a decrease in IL-17 pro-
duction and RORγt gene expression, indicating that the inclusion of
mannose changed cell differentiation away from Th17 and toward Th1
as evidenced by a significant decrease in IL-17 and unchanged levels of
IFN-γ.igate the effect of monosaccharides on T cell differentiation using their cytokine
Th17 cytokines. An increase in IL-10 production can be noted in all conditions
he same conditions also show an increase in IL-17 productions with the highest
d for Man1–Gal2 showing a shift of the immune response away from Th17 and
**p<0.01, ***p<0.001, and ****p<0.0001.
Fig. 7. RT-PCR experiments to quantify FOXP3 and RORγt expression to further
confirm the T cell phenotype. A significant increase in FOXP3 expression can be
seen in Gal1 and Gal1–Gal2. Interestingly, a significant increase in RORγt pro-
duction can be noted in Gal1–Gal2 and Gal1, whereas a reduction is observed in
Man1–Gal2 indicating a possible presence of Th17 and Tregs in the population
for Gal1–Gal2 and Gal1 and the absence of Th17 in Man1–Gal2 condition. Data
are shown as mean  SD of triplicates of three independent donors.
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There is increasing interest in biomaterials that are able to modulate
immune responses to promote healing and suppress adverse immune
responses with a significant focus on modulating macrophage phenotype
[40]. There are encouraging data from the use of polymers, small mol-
ecules, and materials with defined shape and topographies that are able
to dampen adverse immune responses [41–44]. However, despite its
importance in determining the fate of implanted materials [45], con-
trolling adaptive immune responses through material engineering has
remained relatively unexplored. The potent immune-modulatory prop-
erties of carbohydrates and many tools available for their modification
and incorporation into existing materials make them attractive candi-
dates for engineering new materials with immune-instructive properties.
The central role of DCs in shaping adaptive immune responses means
that these cells are ideal targets for immune modulation including con-
trolling immune responses against implanted materials [46]. Carbohy-
drates decorating pathogens and tumor cells have been known to trigger
protective or inhibitory immune responses by modulating DC function,
which typically underpin immune evasion or survival of tumors [47,48].
The latter is mainly through skewing DCs’ response from inflammatory to
tolerogenic, which in turn suppresses the immune responses against
tumor cells [49]. This is in line with our data showing that a number of
‘hit’ conditions (e.g. Gal1, Gal1–Gal2, Man1–Gal2, Man2–Gal2, and
Man1–Man2) were able to induce a regulatory phenotype in DCs as
evidenced by a significant reduction in the expression of co-stimulatory
molecule CD40 and increase in tolerogenic CD274 (PDL-1) expressions
in LPS-challenged DCs. CD40 has been shown to play an important role in
supporting pro-inflammatory responses and Th1 differentiation through
engaging CD154 (or CD40L) on T cells which is known to induce high
levels of IL-12 production, a key pro-inflammatory cytokine [38,50],
whereas CD274 (PDL-1) is an inhibitory ligand for T cell activation with a
role in Treg development [51]. This is also consistent with how some
pathogens modulate the immune system in their favor. For example,
Hamilton et al. showed that Fasciola hepatica tegumental glyco-antigens
suppress DC maturation by decreasing CD40 expression in DCs,
contributing to the pathogen survival [52]. Interestingly, our data also
showed that the same group of monosaccharides that suppressed CD40
expression and induced CD274 (PDL-1) expression could significantly8
suppress LPS-induced IDO activity in DCs. IDO is the rate-limiting
enzyme for the catabolism of essential amino acid tryptophan and is
known for its modulatory effects on immune cells and importantly on
DCs through different mechanisms such as depletion of tryptophan and
producing immune-regulatory metabolites like kynurenine [13,35].
Despite some contradictory evidence on the correlation between IDO
activity and DCs function, it is clear that suppression of IDO activity and
reduced tryptophan levels in the microenvironment suppress inflamma-
tory immune responses and could promote immune regulation [53–56].
This is also in line with studies showing increased levels of IDO activity in
tumor environments, which leads to depletion of tryptophan causing DCs
to switch to anergic state and, ultimately, survival of the tumor cells [57,
58]. To understand the importance of monosaccharides immobilization
in the observed effects on DCs, we also treated DCs with a selection of
monosaccharide combinations in soluble form. These experiments
showed that none of the soluble monosaccharide combinations had a
significant impact on IDO activity (Supplementary Fig. 8). These obser-
vations suggest that receptor clustering or conformation of mono-
saccharides play an important role in their immune-modulatory effects
on DCs. Nevertheless, in a large group of pathologies, including auto-
immune and inflammatory diseases as well as adverse pro-inflammatory
responses to implanted materials, ‘regulatory’ monosaccharides that are
able to suppress IDO activity and promote tolerogenic DCs to suppress
excessive inflammation will be highly desirable and could play a signif-
icant role in developing new therapeutic strategies for these groups of
pathologies [46,59,60].
Changes in DCs phenotype and IDO activity in ‘hit’ monosaccharide-
primed DCs are also reflected in their pro- and anti-inflammatory cyto-
kine profile. Specifically, LPS-stimulated DCs cultured on Gal1,
Gal1–Gal2, Man1–Gal2, Man2–Gal2, and Man1–Man2 showed a signifi-
cant suppression in IL-12 production and an increase in IL-10. This is in
line with how glycoantigens in some pathogens modulate DC function.
For example, ManLam is a component of Mycobacterium tuberculosis cell
membrane that is terminated in mannose and its interaction with DC-
SIGN has been shown to suppress DC function through an increase in
IL-10 and a lower IL-12 production [61]. IL-12 is a potent
pro-inflammatory cytokine that plays a key role in immune response
against intracellular pathogens and Th1 cell differentiation, whereas
IL-10 is a signature anti-inflammatory cytokine that promotes Treg dif-
ferentiation and is also produced by these cells playing a key role in
maintaining immune homeostasis and resolution of inflammation after
injury [62]. These data therefore strongly suggest that the ‘hit’
monosaccharide-primed DCs have acquired a tolerogenic phenotype,
which was further confirmed in DC–T cell co-cultures where conditioned
DCs were shown to support naïve T cell differentiation toward Treg
phenotype. It should be noted that the relatively high level of inter-in-
dividual variation in cytokine levels between different donors meant that
despite some marked changes in IL-12 or IL-10 levels in some donors,
these changes did not reach statistical significance. This could be due to
the presence of both high and low responders to monosaccharide com-
binations and/or LPS within the donor population [63]. To account for
inter-individual variation between different donors, we normalized data
for each donor to their data from LPS stimulation.
The ability of ‘hit’ monosaccharide-primed DCs in instructing
downstream adaptive responses highlights the biological relevance of the
monosaccharide-conditioned DCs. Using engineered materials to modu-
late DC function has gained traction in the last few years with promising
results in areas like DC-based cancer vaccination [64,65]. The ability to
generate tolerogenic DCs and skew T cell responses toward Treg using
immobilized monosaccharide combinations such as Gal1, Gal1–Gal2,
Man1–Gal2, Man2–Gal2, and Man1–Man2, therefore, provides exciting
opportunities for using materials ‘decorated’ by a selection of mono-
saccharides for promoting immune regulation in the context of inflam-
matory and autoimmune diseases as well as implanted materials.
Conditions that showed a reduction in CD40 and IDO activity together
with increased IL10 or a decrease in both IL12 and IL10 were selected as
M.A. Alobaid et al. Materials Today Bio 8 (2020) 100080tolerogenic DCs and were taken forward for co-culture with DCs.
T cells’ plasticity and their ability to respond to different signals and
converging distinct signaling pathways are a widely accepted concept
and provide opportunities for fine-tuning their phenotype [66]. Inter-
estingly, the Gal1–Gal2 combination supported a significant increase in
both IL-17 and IL-10 production. This is in line with previous work that
has described regulatory T cells with the capacity to produce IL-17 to be
highly immune suppressive and are believed to be related to tumor
survival [67]. While future work should focus on better understanding of
the impact of monosaccharides on T cell polarization and contribution of
DCs in the observed increase in IL-10 production, the present data sug-
gest that the Gal1–Gal2 combination could prove a useful tool for
developing new immunotherapies against inflammatory conditions
where aberrant immune activation underpins tissue damage. Intrigu-
ingly, inclusion of mannose to either of Gal isoforms led to the sup-
pression of IL-17 production while maintaining high IL-10 levels. This is
broadly in line with the other studies showing that mannose moieties
support IL-10 production [61,68].
5. Conclusions
In this study, we screened a combinatorial library of immobilized
monosaccharides for their ability to modulate phenotypical and func-
tional properties of DCs. This resulted in identifying a number of amino-
monosaccharides (galactose and mannose with amines at positions 1 or
2; Gal1, Man1–Gal1, Man1–Gal2, and Gal1–Gal2) that induce differen-
tiation of tolerogenic DCs, able to support naïve T cell differentiation
toward Treg phenotype. Our data also show that 1-amino galactose and
2-amino galactose (Gal1–Gal2)-primed DCs support Tregs that also pro-
duce high levels of IL-17, a T cell phenotype that is expected to be highly
immune suppressive. These data will provide a basis for the rational
design of monosaccharide-coated surfaces with immune-regulatory
properties with the ability to fine-tune innate and adaptive immune re-
sponses with applications in materials-based immunotherapy for in-
flammatory conditions and implanted medical devices where
suppressing adverse immune responses is desirable. Future work should
focus on investigating the efficacy of ‘hit’monosaccharides in preclinical
models.
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